CVE:MBI - Med Biogene Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
C$0.05 +0.01 (+25.00 %)
(As of 04/24/2019 06:26 AM ET)
Previous CloseC$0.04
Today's RangeC$0.05 - C$0.05
52-Week RangeC$0.02 - C$0.12
Volume62,000 shs
Average Volume46,050 shs
Market CapitalizationC$437,900.00
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Med BioGene Inc., a life science company, focuses on the development and commercialization of genomic-based clinical laboratory diagnostic tests for cancer. Its products include the GeneFx Lung, a gene expression-based test for early-stage non-small-cell lung cancer that assists in identifying patients for adjuvant chemotherapy. The company has a collaboration agreement with the University Health Network in Toronto. Med BioGene Inc. was founded in 2002 and is headquartered in Vancouver, Canada.

Receive MBI News and Ratings via Email

Sign-up to receive the latest news and ratings for MBI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-604-7327332

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book ValueC($0.02) per share

Profitability

Miscellaneous

EmployeesN/A
Market CapC$437,900.00
Next Earnings Date5/29/2019 (Estimated)
OptionableOptionable

Med Biogene (CVE:MBI) Frequently Asked Questions

What is Med Biogene's stock symbol?

Med Biogene trades on the Canadian Venture Exchange (CVE) under the ticker symbol "MBI."

When is Med Biogene's next earnings date?

Med Biogene is scheduled to release their next quarterly earnings announcement on Wednesday, May 29th 2019. View Earnings Estimates for Med Biogene.

Has Med Biogene been receiving favorable news coverage?

News coverage about MBI stock has trended somewhat positive on Wednesday, InfoTrie reports. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Med Biogene earned a news impact score of 1.6 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the company's share price in the near future.

Who are some of Med Biogene's key competitors?

Who are Med Biogene's key executives?

Med Biogene's management team includes the folowing people:
  • Dr. Iain Weir-Jones Ph.D., P.Eng., FGS, Chairman & CEO
  • Mr. Ibrahim Ghobrial, Chief Financial Officer

How do I buy shares of Med Biogene?

Shares of MBI and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Med Biogene's stock price today?

One share of MBI stock can currently be purchased for approximately C$0.05.

How big of a company is Med Biogene?

Med Biogene has a market capitalization of C$437,900.00.

What is Med Biogene's official website?

The official website for Med Biogene is http://www.medbiogene.com/.

How can I contact Med Biogene?

Med Biogene's mailing address is 598 E Kent Ave South, VANCOUVER, BC V5X 4V6, Canada. The company can be reached via phone at +1-604-7327332.


MarketBeat Community Rating for Med Biogene (CVE MBI)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  43 (Vote Outperform)
Underperform Votes:  45 (Vote Underperform)
Total Votes:  88
MarketBeat's community ratings are surveys of what our community members think about Med Biogene and other stocks. Vote "Outperform" if you believe MBI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MBI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel